SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Chugai stops Gym329 obesity development, returns license and resumes SMA work

Reuters says Chugai Pharmaceutical Co Ltd is discontinuing development of Gym329 (Emugrobart) for obesity, returning the license and resuming development for SMA.

4519.T

Related stories